Findings

What do systematic reviews say?

4,929 questions · 15,174 findings · 2,372 reviews

Sort:Best matchNewestHighest certainty Download CSV

No studies found 15,174 · 100%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Open reduction vs closed reduction position

Functional outcomes · children with displaced supracondylar elbow fractures

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating supracondylar elbow fractures in children 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Open reduction vs closed reduction position

Treatment failure requiring re‐intervention · children with displaced supracondylar elbow fractures

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating supracondylar elbow fractures in children 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Open reduction vs closed reduction position

Cosmetic deformity measured as presence of cubitus varus · children with displaced supracondylar elbow fractures

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating supracondylar elbow fractures in children 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Surgical fixation vs non‐surgical immobilisation

Functional outcomes · children with displaced fractures

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating supracondylar elbow fractures in children 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

Exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

Participant‐reported symptom score Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

Sputum: volume · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

Quality of life Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

Exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

Participant‐reported symptom score Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs placebo

Quality of life Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

FVC (% predicted) Change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists

Sputum: volume · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Short‐acting inhaled muscarinic antagonists vs placebo

Quality of life Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Short‐acting inhaled bronchodilators for cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Heparin started before vs after the surgical procedure

PE · people undergoing bariatric surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Heparin started before vs after the surgical procedure

Thrombocytopenia · people undergoing bariatric surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IPC plus pharmacological prophylaxis vs mechanical prophylaxis alone

PE · people undergoing bariatric surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

IPC plus pharmacological prophylaxis vs mechanical prophylaxis alone

Adverse events · people undergoing bariatric surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found